PE20061167A1 - Composicion farmaceutica que comprende moduladores de fosfodiesterasa pde4 - Google Patents
Composicion farmaceutica que comprende moduladores de fosfodiesterasa pde4Info
- Publication number
- PE20061167A1 PE20061167A1 PE2005001269A PE2005001269A PE20061167A1 PE 20061167 A1 PE20061167 A1 PE 20061167A1 PE 2005001269 A PE2005001269 A PE 2005001269A PE 2005001269 A PE2005001269 A PE 2005001269A PE 20061167 A1 PE20061167 A1 PE 20061167A1
- Authority
- PE
- Peru
- Prior art keywords
- pharmaceutical composition
- propionamide
- composition including
- phosphodiesterase pde4
- phenyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Indole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A) UN MODULADOR DE FOSFODIESTERASA PDE4 TAL COMO 3-(3,4-DIMETOXI-FENILO)-3-(1-OXO-1,3-DIHIDRO-ISOINDOL-2-IL)-PROPIONAMIDA, 3-FENIL-2-(1-OXOISOINDOLIN-2-IL)PROPIONAMIDA, 3-(3-ETOXI-4METOXIFENIL)-N-HIDROXI-3-(1-OXOISOINDOLINIL)PROPIONAMIDA, ENTRE OTROS, CUYO RANGO DE DOSIS DIARIA ES DE 1mg A 10000mg POR DIA; B) UN AGENTE ACTIVO SECUNDARIO TAL COMO ANTIINFLAMATORIOS, ANTIHIPERTENSIVOS, ANTICONVULSIVANTES, BENZODIACEPINAS, ENTRE OTROS. DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DE LESIONES DEL SISTEMA NERVIOSO CENTRAL TAL COMO LESION CEREBRAL FOCAL, LESION AXONAL DIFUSA, HEMATOMA SUBDURAL, EPILEPSIA POST TRAUMATICA
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62380304P | 2004-10-28 | 2004-10-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20061167A1 true PE20061167A1 (es) | 2006-11-08 |
Family
ID=36319648
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2005001269A PE20061167A1 (es) | 2004-10-28 | 2005-10-28 | Composicion farmaceutica que comprende moduladores de fosfodiesterasa pde4 |
Country Status (14)
Country | Link |
---|---|
US (1) | US20060106085A1 (es) |
EP (1) | EP1811992A2 (es) |
JP (1) | JP2008518924A (es) |
KR (1) | KR20070085454A (es) |
CN (1) | CN101309585A (es) |
AR (1) | AR052223A1 (es) |
AU (1) | AU2005302523A1 (es) |
BR (1) | BRPI0518062A (es) |
CA (1) | CA2585423A1 (es) |
IL (1) | IL182825A0 (es) |
MX (1) | MX2007005040A (es) |
PE (1) | PE20061167A1 (es) |
WO (1) | WO2006050057A2 (es) |
ZA (1) | ZA200704251B (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050100529A1 (en) * | 2003-11-06 | 2005-05-12 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders |
JP2009512711A (ja) * | 2005-10-21 | 2009-03-26 | ブレインセルス,インコーポレイティド | Pde阻害による神経新生の調節 |
JP5352452B2 (ja) * | 2006-06-06 | 2013-11-27 | メディシノバ, インコーポレイテッド | 置換ピラゾロ[1,5−a]ピリジン化合物およびその使用方法 |
PT2231640E (pt) * | 2008-01-24 | 2012-08-23 | Merck Patent Gmbh | Derivados beta-aminoácido para o tratamento de diabetes |
MX2013007959A (es) * | 2011-01-10 | 2013-12-06 | Celgene Corp | Formas farmaceuticas orales de amida {2-[(1s)-1-(3-etoxi-4-metoxi- fenil]-2-metansulfonil-etil]-3-oxo-2,,3-dihidro-1h-isoindol -4-il}-del acido ciclopropancarboxilico. |
US8865723B2 (en) | 2012-10-25 | 2014-10-21 | Tetra Discovery Partners Llc | Selective PDE4 B inhibition and improvement in cognition in subjects with brain injury |
US10011611B2 (en) | 2015-08-14 | 2018-07-03 | Reaction Biology Corp. | Histone deacetylase inhibitors and methods for use thereof |
JP2022518292A (ja) * | 2019-01-23 | 2022-03-14 | パス セラピューティクス,インク. | ホスホジエステラーゼ4(pde4)阻害によるてんかんの治療方法 |
US11999694B2 (en) | 2021-10-29 | 2024-06-04 | Sensorium Therapeutics, Inc. | Delivery of therapeutic alkaloid compounds |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US570302A (en) * | 1896-10-27 | Weighing-machine | ||
US3536809A (en) * | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
US3598123A (en) * | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3845770A (en) * | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) * | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US4008719A (en) * | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
US4215114A (en) * | 1976-11-12 | 1980-07-29 | The Upjohn Company | Analgesic N-[2-(furyl-methylamino and 2-thienylmethylamino)cycloaliphatic]be |
IE58110B1 (en) * | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
US5073543A (en) * | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
IT1229203B (it) * | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
US5120548A (en) * | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
KR0166088B1 (ko) * | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
US5733566A (en) * | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
US5580578A (en) * | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
US5591767A (en) * | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
US5629327A (en) * | 1993-03-01 | 1997-05-13 | Childrens Hospital Medical Center Corp. | Methods and compositions for inhibition of angiogenesis |
US5605914A (en) * | 1993-07-02 | 1997-02-25 | Celgene Corporation | Imides |
US5463063A (en) * | 1993-07-02 | 1995-10-31 | Celgene Corporation | Ring closure of N-phthaloylglutamines |
US5698579A (en) * | 1993-07-02 | 1997-12-16 | Celgene Corporation | Cyclic amides |
DK0923933T3 (da) * | 1993-11-30 | 2002-10-21 | Searle & Co | Substituerede pyrazolyl-benzensulfonamider til anvendelse ved behandling af inflammation |
IT1270594B (it) * | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
US6429221B1 (en) * | 1994-12-30 | 2002-08-06 | Celgene Corporation | Substituted imides |
US5703098A (en) * | 1994-12-30 | 1997-12-30 | Celgene Corporation | Immunotherapeutic imides/amides |
US5801195A (en) * | 1994-12-30 | 1998-09-01 | Celgene Corporation | Immunotherapeutic aryl amides |
US6518281B2 (en) * | 1995-08-29 | 2003-02-11 | Celgene Corporation | Immunotherapeutic agents |
US5728844A (en) * | 1995-08-29 | 1998-03-17 | Celgene Corporation | Immunotherapeutic agents |
US5728845A (en) * | 1995-08-29 | 1998-03-17 | Celgene Corporation | Immunotherapeutic nitriles |
US5658940A (en) * | 1995-10-06 | 1997-08-19 | Celgene Corporation | Succinimide and maleimide cytokine inhibitors |
US5635517B1 (en) * | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
HU228769B1 (en) * | 1996-07-24 | 2013-05-28 | Celgene Corp | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha |
US6281230B1 (en) * | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
US5798368A (en) * | 1996-08-22 | 1998-08-25 | Celgene Corporation | Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels |
DK0918746T3 (da) * | 1996-08-12 | 2003-08-04 | Celgene Corp | Immunterapeutiske midler og deres anvendelse til reduktion af cytokinniveauer |
NZ502379A (en) * | 1997-07-31 | 2002-10-25 | Celgene Corp | Substituted alkanohydroxamic acids and use in pharmaceuticals for reducing TNF-alpha levels |
US5874448A (en) * | 1997-11-18 | 1999-02-23 | Celgene Corporation | Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels |
US5955476A (en) * | 1997-11-18 | 1999-09-21 | Celgene Corporation | Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels |
TR200101503T2 (tr) * | 1998-03-16 | 2002-06-21 | Celgene Corporation | 2-(2,6-dioksopiperidin-3-il) izoindolin türevleri, bunların hazırlanması ve enflamatuar sitokinlerin inhibitörleri olarak kullanımı |
SE9803710L (sv) * | 1998-09-25 | 2000-03-26 | A & Science Invest Ab | Användning av vissa substanser för behandling av nervrotsskador |
US20030087962A1 (en) * | 1998-10-20 | 2003-05-08 | Omeros Corporation | Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation |
US6020358A (en) | 1998-10-30 | 2000-02-01 | Celgene Corporation | Substituted phenethylsulfones and method of reducing TNFα levels |
US6177077B1 (en) * | 1999-02-24 | 2001-01-23 | Edward L. Tobinick | TNT inhibitors for the treatment of neurological disorders |
KR100672892B1 (ko) * | 1999-03-18 | 2007-01-23 | 셀진 코오퍼레이션 | 치환된 1-옥소- 및 1,3-디옥소이소인돌린스 및 염증성사이토킨 수치를 감소시키기 위한 약학적 조성물로서의이들의 사용 |
US6667316B1 (en) * | 1999-11-12 | 2003-12-23 | Celgene Corporation | Pharmaceutically active isoindoline derivatives |
US6326388B1 (en) * | 1999-12-21 | 2001-12-04 | Celgene Corporation | Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha level |
US6699899B1 (en) * | 1999-12-21 | 2004-03-02 | Celgene Corporation | Substituted acylhydroxamic acids and method of reducing TNFα levels |
US6458810B1 (en) * | 2000-11-14 | 2002-10-01 | George Muller | Pharmaceutically active isoindoline derivatives |
US7091353B2 (en) * | 2000-12-27 | 2006-08-15 | Celgene Corporation | Isoindole-imide compounds, compositions, and uses thereof |
US20030045552A1 (en) * | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
US20040038874A1 (en) * | 2002-08-22 | 2004-02-26 | Osemwota Omoigui | Method of treatment of persistent pain |
-
2005
- 2005-10-26 KR KR1020077011855A patent/KR20070085454A/ko not_active Application Discontinuation
- 2005-10-26 ZA ZA200704251A patent/ZA200704251B/xx unknown
- 2005-10-26 CN CNA2005800452239A patent/CN101309585A/zh active Pending
- 2005-10-26 BR BRPI0518062-7A patent/BRPI0518062A/pt not_active IP Right Cessation
- 2005-10-26 EP EP05814094A patent/EP1811992A2/en not_active Withdrawn
- 2005-10-26 CA CA002585423A patent/CA2585423A1/en not_active Abandoned
- 2005-10-26 WO PCT/US2005/038861 patent/WO2006050057A2/en active Application Filing
- 2005-10-26 AU AU2005302523A patent/AU2005302523A1/en not_active Abandoned
- 2005-10-26 MX MX2007005040A patent/MX2007005040A/es not_active Application Discontinuation
- 2005-10-26 JP JP2007539148A patent/JP2008518924A/ja not_active Abandoned
- 2005-10-27 AR ARP050104509A patent/AR052223A1/es not_active Application Discontinuation
- 2005-10-27 US US11/262,374 patent/US20060106085A1/en not_active Abandoned
- 2005-10-28 PE PE2005001269A patent/PE20061167A1/es not_active Application Discontinuation
-
2007
- 2007-04-26 IL IL182825A patent/IL182825A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
US20060106085A1 (en) | 2006-05-18 |
CA2585423A1 (en) | 2006-05-11 |
JP2008518924A (ja) | 2008-06-05 |
IL182825A0 (en) | 2007-09-20 |
AU2005302523A1 (en) | 2006-05-11 |
EP1811992A2 (en) | 2007-08-01 |
AR052223A1 (es) | 2007-03-07 |
BRPI0518062A (pt) | 2008-10-28 |
CN101309585A (zh) | 2008-11-19 |
WO2006050057A2 (en) | 2006-05-11 |
ZA200704251B (en) | 2008-11-26 |
WO2006050057A3 (en) | 2008-07-10 |
KR20070085454A (ko) | 2007-08-27 |
MX2007005040A (es) | 2007-06-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20061167A1 (es) | Composicion farmaceutica que comprende moduladores de fosfodiesterasa pde4 | |
CL2007003827A1 (es) | Compuestos derivados de n-(2-aza-biciclo(3.1.0)hex-3-ilmetil)amida; y su uso para prevenir o tratar la depresion, neurosis, esquizofrenia, ansiedad, adicciones, epilepsia, dolor, enfermedades cardiacas, entre otras. | |
CL2011000144A1 (es) | Compuestos derivados de benzo (1,4) dioxin-2-ilmetil-sulfamida; composiciones farmaceuticas que los contienen; proceso para prepararlos y uso en el tratamiento de la ansiedad, epilepsia, dolor, abuso de sustancias, trastornos relacionados, entre otros. | |
BRPI0918868B8 (pt) | compostos moduladores do receptor de nmda e composições compreendendo os mesmos | |
ECSP077275A (es) | Novedosos derivados de heteroarilsulfamida benzofusionados utiles como agentes anticonvulsivos | |
CL2011002206A1 (es) | Compuestos derivados de benzofurano sustituidos, moduladores del señalador igf1 o activador de la proteina quinasa b; composicion farmaceutica que los comprende; utiles en el tratamiento de enfermedades del snc, tales como alzheimer, entre otras. | |
HN2010002774A (es) | DERIVADOS DE 2-(1,5-DIHIDRO-5-OXO-1,2,4-TRIAZOL-4-IL/2-OXOIMIDAZOLIDIN-1-IL)PIRIDIN-4-CARBOXAMIDA ACTIVOS COMO MODULADORES DE ESTEAROIL-CoA | |
CL2012001673A1 (es) | Compuestos derivados de benzamida sustituidos, como moduladores de taar; procedimiento de preparación; composición farmacéutica; y su uso en el tratamiento de la depresión, trastornos de ansiedad, trastorno bipolar, esquizofrenia, epilepsia, migraña, enfermedad de alzheimer, trastornos metabolicos, entre otras. | |
BRPI0518869A2 (pt) | agentes citotàxicos compreendendo taxanos | |
CL2013001073A1 (es) | Compuestos derivados de 6-amino-nicotinamidas sustituidas, como moduladores de kcnq2/3; composicion farmaceutica que los comprende, util para el tratamiento y/o profilaxis de trastornos y/o enfermedades seleccionadas de dolor, epilepsia, ansiedad, enfermedades cognitivas, entre otras. | |
ES2156603T3 (es) | Medicamentos a base de una mezcla sinergetica de metronidazol y de clindamicina. | |
BR112014009851A2 (pt) | moduladores de receptor de nmda e usos dos mesmos | |
AR047112A1 (es) | Composiciones de adn estabilizado para recubrir microproyecciones | |
NI200700010A (es) | Moduladores de los receptores de alfa 7 acetilcolina nicotinica y sus usos terapéuticos | |
ECSP077309A (es) | Compuestos amido y sus usos como farmaceuticos | |
EA200702253A1 (ru) | Фармацевтическая композиция | |
CL2011001714A1 (es) | Compuestos derivados de bencenosulfonamidas, bloqueadores de canales de calcio; composicion farmaceutica que los comprende; uso en el tratamiento del dolor y enfermedades del snc. | |
ATE476969T1 (de) | Verwendung filmbildender haarpflegepolymere aus der gruppe der polyurethane und diese polymere enthaltende pharmazeutische zubereitungen und pflaster | |
PE20070432A1 (es) | Dispositivos de administracion transdermicas de farmacos que contienen o-desmetilvenlafaxina (odv) o sus sales | |
AR023966A1 (es) | Una composicion farmaceutica para la prevencion y/o el tratamiento de la enfermedad de parkinson y los sintomas concomitantes de la misma, y el uso de unantagonista dual receptor de adenosina a1 a2a para preparar dicha composicion | |
BRPI0618493A2 (pt) | composições farmacêuticas e usos das mesmas para o tratamento de distúrbios do snc | |
CL2009000980A1 (es) | Uso de (s)-n-(2-(1,6,8-tetrahidro-2h-inden[5,4-b]furan-8-il)etil]propionamida en combinacion con una o más drogas seleccionadas de un grupo definido para preparar un medicamento útil para la prevencion o tratamiento de la depresión o desórdenes de ansiedad (divisional de la solicitud 749-2006). | |
PE20011049A1 (es) | Combinacion de farmacos para el tratamiento de la depresion y trastornos relacionados que comprenden mirtazapina | |
BRPI0511125A (pt) | usos de ácido 5,6,7-triidroxieptanóico seus e análogos | |
UY27177A1 (es) | Novedosos derivados heterocíclicos de la urea y sus usos como ligandos del receptor d3 de la dopamina. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |